rs200997384
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 4P and 5B. PM1PM2BP4_StrongBP6
The NM_006361.6(HOXB13):c.832G>T(p.Val278Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000904 in 1,614,186 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_006361.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HOXB13 | NM_006361.6 | c.832G>T | p.Val278Leu | missense_variant | 2/2 | ENST00000290295.8 | NP_006352.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HOXB13 | ENST00000290295.8 | c.832G>T | p.Val278Leu | missense_variant | 2/2 | 1 | NM_006361.6 | ENSP00000290295.8 |
Frequencies
GnomAD3 genomes AF: 0.000131 AC: 20AN: 152182Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000262 AC: 66AN: 251458Hom.: 1 AF XY: 0.000280 AC XY: 38AN XY: 135898
GnomAD4 exome AF: 0.0000862 AC: 126AN: 1461886Hom.: 1 Cov.: 31 AF XY: 0.0000908 AC XY: 66AN XY: 727244
GnomAD4 genome AF: 0.000131 AC: 20AN: 152300Hom.: 0 Cov.: 32 AF XY: 0.000175 AC XY: 13AN XY: 74478
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 21, 2024 | In silico analysis indicates that this missense variant does not alter protein structure/function; Reported in both prostate cancer cases and unaffected controls (PMID: 22781434, 23555315, 31214711); This variant is associated with the following publications: (PMID: 22696596, 27424772, 22781434, 19389631, 28272408, 25668207, 35734583, 31214711, 23555315, 36243179) - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Aug 26, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 02, 2023 | - - |
Prostate cancer, hereditary, 9 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
HOXB13-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 05, 2024 | The HOXB13 c.832G>T variant is predicted to result in the amino acid substitution p.Val278Leu. This variant was reported as an uncertain germline variant in a study of individuals with biliary tract cancer (Table S2, Okawa et al. 2023. PubMed ID: 36243179). This variant is reported in 0.32% of alleles in individuals of East Asian descent in gnomAD and has conflicting interpretations regarding its pathogenicity in ClinVar, ranging from uncertain significance to likely benign to benign (https://www.ncbi.nlm.nih.gov/clinvar/variation/128038/). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 11, 2023 | The p.V278L variant (also known as c.832G>T), located in coding exon 2 of the HOXB13 gene, results from a G to T substitution at nucleotide position 832. The valine at codon 278 is replaced by leucine, an amino acid with highly similar properties. In one case-control study assessing the association of HOXB13 mutations with prostate cancer, this alteration was detected in 1/2225 controls, but was absent from 1843 cases (Akbari MR et al. J. Natl. Cancer Inst. 2012 Aug;104:1260-2). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at